跳至主要内容
临床试验/NCT02746562
NCT02746562Unknown不适用

A Multicentre Randomized Controlled Trial of a "Freeze All and Transfer Later" Versus a Conventional "Fresh Embryo Transfer" Strategy for Assisted Reproductive Technology (ART) in Women With a Regular Menstrual Cycle

Anja Bisgaard Pinborg2 个研究点 分布在 1 个国家目标入组 424 人开始时间: 2016年5月最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
424
试验地点
2
主要终点
Ongoing pregnancy rates

研究概览

简要总结

The purpose of this study is to compare conventional fresh embryo transfer with a "freeze all and transfer later strategy" in assisted reproductive technology in terms of ongoing pregnancy rates, live birth rates as well as perinatal outcomes.

详细描述

The study is a multicentre randomized controlled double-blinded trial with the purpose to investigate if pregnancy- and live birth rates can be improved by a "freeze all and transfer later"-strategy with transfer of the best quality, frozen, thawed embryo in a subsequent natural cycle compared with conventional fresh embryo transfer with transfer of the embryo in the stimulated cycle.

In total 5 clinics in Denmark and Sweden will be participating in the recruitment of patients for the study.

The patients will be screened and randomized computerized on cycle day 2 or 3 and allocated to one of the two study arms:

I: hCG (human chorion gonadotrophin) arm with traditional hCG triggering and fresh blastocyst transfer II: GnRH (gonadotropin-releasing hormone)- agonist triggering arm with blastocyst cryopreservation and subsequent transfer in a subsequent natural cycle.

The randomization will be done after the decision of gonadotrophin (rFSH/hMG) starting dose, and both doctor and patient will be blinded to the randomization until the day of hCG/agonist trigger. Both groups will be stimulated in a short GnRH antagonist protocol. The ovarian stimulation The gonadotrophin stimulation is performed according to the general standards in each of the clinics and can be altered according to the ovarian response with a maximum of 300 IU.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 39 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • AMH (Anti-Müllerian hormone) > 6.28 pmol/L (Roche Elecsys assay)
  • Female age 18 years to less than 40 years
  • 1, 2 or 3 IVF/ICSI cycle with oocyte aspiration
  • Regular menstrual cycle between 24 and 35 days
  • BMI between 18 and 35
  • Two ovaries
  • Can and will sign informed consent

排除标准

  • Women who do not fulfil the inclusion criteria
  • Endometriosis stage III to IV
  • Ovarian cysts with diameter > 30 mm at day of start of stimulation
  • Submucosal fibroids
  • Women with severe co-morbidity (IDDM, NIDDM, gastrointestinal, cardiovascular, pulmonary, liver or kidney disease)
  • Dysregulation of thyroid disease
  • Not danish or English speaking women
  • Contraindications or allergies to use of Gonadotrophins or GnRH antagonists
  • TESA (testicular sperm aspiration)
  • OD (oocyte donation)
  • Previous inclusion in the study

研究组 & 干预措施

Freeze all

Experimental

Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle

干预措施: Freeze all (Procedure)

Fresh embryo transfer

No Intervention

Standard procedure

结局指标

主要结局

Ongoing pregnancy rates

时间窗: Two years

Outcome measured per transfer of the first blastocyst, per oocyte pick-up, per start of ovarian stimulation and per randomized patient.

次要结局

  • Live birth rates(Two years)
  • Cumulative live birth rates(Two years)
  • Number of cycles with no embryo transfer(Two years)
  • Time-to-pregnancy(Two years)
  • Time-to-delivery(Three years)
  • Preterm birth(Three years)
  • Low birth weight(Three years)
  • Small-for-gestational age (SGA)(Three years)
  • Perinatal mortality(Three years)
  • Large-for-gestational age (LGA)(Three years)
  • Preeclampsia(Three years)
  • Placental rupture(Three years)
  • Positive hCG 11 days post embryo transfer(Three years)
  • Miscarriages, biochemical pregnancies, ectopic pregnancies(Three years)
  • Quality of life for female and partner(Two years)
  • Cost-effectiveness(Three years)

研究者

发起方
Anja Bisgaard Pinborg
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Anja Bisgaard Pinborg

Professor, MD, DMSc

Hvidovre University Hospital

研究点 (2)

Loading locations...

相似试验